Piper Jaffray Raises Target on Affymax (AFFY) to $19 Amid Optimistic Peginesatide Numbers

Article Stock Quotes (1) Comments (0)

Shares of Affymax (Nasdaq: AFFY) are catching a bid Thursday morning as Piper Jaffray's Ian Somaiya (one of just eight analysts who cover the stock) boosted estimates for the company earlier.

Following a recent meeting with Affymax managers, Somaiya is now more bullish on the long-term prospects for the company's peginesatide product. The analyst raised his FY15 adj-EPS estimate from $1.38 to $1.57.

Somaiya lifted his target on Affymax shares from $17 to $19. With Affymax shares last trading at $9.59, up 7.8 percent from Wednesday's close, the analyst's new price target represents potential upside of about 98 percent.

The firm maintains an Overweight rating on Affymax shares.

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Affymax.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
• Wedbush Upgrades Pacific Sunwear of California (PSUN) to Neutral
• Toll Bros. (TOL) Q2 Solid but Not Much Better Than Peers

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Piper Jaffray

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?